CLIP2 Genotype

Most people will never think about CLIP2 (CAP-Gly domain containing linker protein 2), but it sits inside a small stretch of chromosome 7 that gets a lot of clinical attention. That region, called 7q11.23, contains roughly 25 to 28 genes that are deleted together in Williams-Beuren syndrome, a developmental condition with heart, facial, and cognitive features. CLIP2 is one of those neighbors, and it has also drawn interest as a possible signature of radiation-related papillary thyroid cancer.

Testing your CLIP2 genotype tells you whether your sequence at this gene matches the expected reference, whether you have lost one copy through a deletion, or whether you carry a variant of unclear meaning. It is a research-grade marker rather than a routine clinical lab. Knowing your result can be useful context if you have a personal or family history of conditions linked to the 7q11.23 region, but it does not stand alone as a diagnosis.

What CLIP2 Does in the Body

CLIP2 codes for a protein that helps shape the internal skeleton of cells, the network of microtubules that gives cells structure and moves cargo around inside them. The gene is active in many tissues, including the brain, where animal studies have suggested a role in neurological development. In humans, however, isolated changes in CLIP2 have produced surprisingly mild effects.

A case report of two adult siblings who each carried a small deletion limited to CLIP2 found them clinically normal. They had typical height, no Williams-Beuren facial or heart features, and average or above-average IQ without the distinctive cognitive pattern seen in the full syndrome. Laboratory testing of their cells confirmed CLIP2 haploinsufficiency, with the remaining single copy producing reduced protein levels reported in the full text of that case report, yet they had no apparent disease from it.

Williams-Beuren Syndrome and the 7q11.23 Region

Williams-Beuren syndrome is caused by a roughly 1.5 to 1.8 megabase deletion at 7q11.23 that removes about 25 to 28 genes at once. People with this larger deletion can have supravalvar aortic stenosis (a narrowing of the artery leaving the heart), distinctive facial features, intellectual disability, and an unusual cognitive profile with relatively strong verbal skills but weaker visuospatial reasoning. CLIP2, GTF2I, and GTF2IRD1 have all been studied as possible contributors to that cognitive pattern.

The data on isolated CLIP2 loss reframe its role. Because the two siblings with a CLIP2-only deletion did not show the syndrome, current thinking is that GTF2I and GTF2IRD1 are the more important drivers of the Williams-Beuren cognitive phenotype, while CLIP2 may act as a modifier when it is deleted alongside its neighbors. A separate observational study of 162 people evaluated for supravalvar aortic stenosis found that when Williams-Beuren syndrome is ruled out, sequencing other genes (most often ELN) provides the highest diagnostic yield.

This is a key reason why a CLIP2 result alone rarely answers a clinical question. If you are being evaluated for features that overlap with Williams-Beuren syndrome, the larger 7q11.23 region, the ELN gene, and broader chromosomal microarray testing carry more diagnostic weight than CLIP2 by itself.

Reconciling a Counterintuitive Finding

It can feel paradoxical that losing a copy of a gene active in the brain produces no obvious disease, while losing the same gene as part of a larger deletion seems to matter. The resolution is that CLIP2 is best understood as a contextual modifier, not a stand-alone disease gene. Its effect appears to depend on what is happening in the genes around it. That framing also explains why this test is not a yes-or-no answer about your health: it is one data point in a regional puzzle.

Radiation-Related Papillary Thyroid Cancer

A separate line of human research has examined CLIP2 in thyroid tumor tissue, not in your bloodstream. In papillary thyroid cancers from people exposed to radioiodine fallout after the Chernobyl accident, tumors showed extra copies of the chromosome region containing CLIP2 and higher CLIP2 messenger RNA and protein levels compared with non-exposed cases. A laboratory workflow built on these findings could sort tumors into CLIP2-positive and CLIP2-negative groups with high sensitivity and specificity across three cohorts.

A follow-up dose-response analysis of 117 cases found that CLIP2 expression in tumor tissue tracked with the radiation dose received in childhood, with a clear relationship in younger cases. The mechanistic context, drawn from network analyses, points to genes involved in cell death signaling, the MAPK pathway, and chromosome stability. These tumor-tissue findings do not mean that your inherited CLIP2 genotype predicts thyroid cancer, but they do explain why the gene is studied as a marker of past radiation exposure.

One-Time Result

Your CLIP2 genotype is set at conception and stays the same for life. There is no value in retesting the gene itself once you have a confirmed result from a clinical-grade laboratory. The value of testing lies in integrating the result into how you think about the 7q11.23 region as a whole. If your result is unexpected or borderline, a single confirmatory test by a different method (for example, Sanger sequencing after a chip-based call) is reasonable.

What you should track over time, if relevant to your situation, are downstream phenotypes rather than the genotype itself. Echocardiography for anyone with supravalvar aortic stenosis features in the family, neurodevelopmental follow-up for children, and routine thyroid examination for anyone with a history of childhood radiation exposure all carry more practical weight than retesting CLIP2.

When Results Can Be Misleading

Genetic testing has its own set of pitfalls that differ from standard blood tests. The most relevant ones for CLIP2 are:

• Panel coverage limits: the assay only finds the variants it is designed to look for. A negative result does not rule out other rare changes in CLIP2 or in nearby genes that may be more clinically important.
• Ancestry-specific frequencies: variants seen on this test may be common in some populations and very rare in others, which changes how a result should be interpreted.
• Variants of uncertain significance: an unexpected change in CLIP2 may be flagged with no clear meaning, because the published evidence base for this gene is small.
• Direct-to-consumer vs clinical-grade differences: a CLIP2 call on a consumer ancestry report is not equivalent to a clinical genetics report, and unexpected findings should be confirmed in a clinical laboratory before being acted on.

Decision Pathway for an Unexpected Result

If your CLIP2 result is unexpected, the next steps depend on your overall picture. If you carry a deletion limited to CLIP2 and you have no Williams-Beuren features, the published case data suggest the finding is likely benign, but a genetics consultation is the appropriate place to confirm that interpretation.

If you have features that overlap with Williams-Beuren syndrome (supravalvar aortic stenosis, characteristic facial features, developmental delay), broader testing is the priority. That usually means chromosomal microarray or a multigene panel that covers the entire 7q11.23 region, including GTF2I, GTF2IRD1, and ELN. A cardiology evaluation with echocardiography is reasonable if any heart symptoms are present. A genetic counselor can help map out which biological relatives may benefit from testing, given that 7q11.23 deletions can occur de novo or be inherited.

If you have a personal history of childhood radiation exposure and a thyroid nodule has been found, the CLIP2 tumor-tissue research is relevant to your pathologist, not to your germline genotype. Clinical decisions in that case rest on standard thyroid nodule evaluation, not on this test.